by Ken Snyder

Regeneron is a leading biotechnology and pharmaceutical company that invents life-transforming medicines for people with serious diseases. The Regeneron Industrial Operations & Product Supply Group received a Shingo Prize in 2019.

It has been difficult to keep up with all the news coming out about Regeneron. It’s an impressive list. Let me highlight just two stories:

1) On March 16th, Regeneron announced the start of the Kevzara® clinical trial with partner Sanofi. This is an antibody treatment for severe COVID-19 patients. Here’s the press release:
https://newsroom.regeneron.com/index.php/news-releases/news-release-details/regeneron-and-sanofi-begin-global-kevzarar-sarilumab-clinical

2) The following day, on March 17th, Regeneron announced the start of an antibody cocktail trial. This trial is based on the thinking behind the Ebola treatment developed by Regeneron. It could eventually be an early-stage treatment of COVID-19. Here’s the press release:
https://newsroom.regeneron.com/index.php/news-releases/news-release-details/regeneron-announces-important-advances-novel-covid-19-antibody

I could go on with more examples. The point is that when you are part of a focused, well-run organization, its people can quickly direct efforts to finding solutions—even in a pandemic. That is precisely what Regeneron has done and keeps on doing.